Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic

Bibliography

• SUERBAUM S, MICHETTI P: Helicobacter pylori infection. N. Engl. J. Med. (2002) 347:1175-1186.
   PubMed Web of Science ®Google Scholar
• EL-OMAR EM, CARRINGTON M, CHOW WH et al.: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature (2000) 404:398-402.
   PubMed Web of Science ®Google Scholar
• El-OMAR EM, CHOW WH, RABKIN CS: Gastric cancer and H. pylori: Host genetics open the way. Gastroenterology (2001) 121(4):1002-1004.
   PubMedGoogle Scholar
• EL-OMAR EM, OIEN K, MURRAY LS et al.: Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology (2000) 118:22-30.
   PubMed Web of Science ®Google Scholar
• EL-OMAR EM, RABKIN CS, GAMMON MD et al.: Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 124:1193-1201.
   PubMed Web of Science ®Google Scholar
• FURUTA T, EL-OMAR EM, XIAO F et al.: Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology (2002) 123:92-105.
   PubMed Web of Science ®Google Scholar
• PENSTON JG: Review article: clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Aliment Pharmacol. Ther. (1996) 10:469-486.
   PubMed Web of Science ®Google Scholar
• TREIBER G, LAMBERT JR: The impact of Helicobacter pylori eradication on peptic ulcer healing. Am. J. Gastroenterol. (1998) 93(7):1080-1084.
   PubMed Web of Science ®Google Scholar
• FORD A, DELANEY B, FORMAN D, MOAYYEDI P: Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst. Rev. (2004) 4:CD003840.
   Google Scholar
• MALFERTHEINER P, MEGRAUD F, O’MORAIN C et al.: Current concepts in the management of Helicobacter pylori infection-the Maastricht III Consensus Report. Gut (2006) (In press).
   Google Scholar
• PETERSON WL, FENDRICK AM, CAVE DR et al.: Helicobacter pylori-related disease: guidelines for testing and treatment. Arch. Intern. Med. (2000) 160:1285-1291.
   PubMed Web of Science ®Google Scholar
• UEMURA N, OKAMOTO S: Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol. Clin. North Am. (2000) 29(4):819-827.
   PubMedGoogle Scholar
• UEMURA N, OKAMOTO S, YAMAMOTO S et al.: Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. (2001) 345:784-789.
   PubMed Web of Science ®Google Scholar
• WONG BC, LAM SK, WONG WM et al.: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA (2004) 291(2):187-194.
   PubMed Web of Science ®Google Scholar
• HUANG JQ, ZHENG GF, SUMANAC K, IRVINE EJ, HUNT RH: Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology (2003) 125(6):1636-1644.
   PubMed Web of Science ®Google Scholar
• HUNT RH: Will eradication of Helicobacter pylori infection influence the risk of gastric cancer? Am. J. Med. (2004)117(Suppl. 5A):86S-91S.
   PubMed Web of Science ®Google Scholar
• YAMAOKA Y, OJO O, FUJIMOTO S et al.: Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut (2006) 55(6):775-781
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, SHIOTANI A: The time to eradicate gastric cancer is now. Gut (2005) 54:735-738.
   PubMed Web of Science ®Google Scholar
• AEBISCHER T, SCHMITT A, WALDUCK AK, MEYER TF: Helicobacter pylori vaccine development: facing the challenge. Int. J. Med. Microbiol. (2005) 295(5):343-353.
   PubMed Web of Science ®Google Scholar
• DEL GIUDICE G, COVACCI A, TELFORD JL, MONTECUCCO C, RAPPUOLI R: The design of vaccines against Helicobacter pylori and their development. Ann. Rev. Immunol. (2001) 19:523-563.
   Google Scholar
• ERNST PB, PEURA DA, CROWE SE: The translation of Helicobacter pylori basic research to patient care. Gastroenterology (2006) 130(1):188-206; quiz 212-3.
   PubMed Web of Science ®Google Scholar
• LOUGHLIN MF: Novel therapeutic targets in Helicobacter pylori. Expert. Opin. Ther. Targets (2003) 7:725-735.
   PubMed Web of Science ®Google Scholar
• MALFERTHEINER P, PEITZ U, TREIBER G:What constitutes failure for Helicobacter pylori eradication therapy? Can. J. Gastroenterol. (2003) 17 (Suppl. B):53B-57B.
   PubMedGoogle Scholar
• CONWAY BR: Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr. Pharm. Des. (2005) 11:775-790.
   PubMed Web of Science ®Google Scholar
• SACHS G: Proton pump inhibitors and acid-related diseases. Pharmacotherapy (1997) 17:22-37.
   PubMed Web of Science ®Google Scholar
• KLOTZ U: Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin. Pharmacokinet. (2000) 38:243-270.
   PubMed Web of Science ®Google Scholar
• FURUTA T, SHIRAI N, SUGIMOTO M, OHASHI K, ISHIZAKI T: Pharmacogenomics of proton pump inhibitors. Pharmacogenomics (2004) 5(2):181-202.
   PubMed Web of Science ®Google Scholar
• KLOTZ U, SCHWAB M, TREIBER G: CYP2C19 polymorphism and proton pump inhibitors. Basic Clin. Pharmacol. Toxicol. (2004) 95(1):2-8.
   PubMed Web of Science ®Google Scholar
• PADOL S, YUAN Y, THABANE M, PADOL IT, HUNT RH: The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol. (2006) 101:1467-1475
   PubMed Web of Science ®Google Scholar
• SCHWAB M, KLOTZ U, HOFMANN UG et al.: Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin. Pharmacol. Ther. (2005) 78(6):627-634.
   PubMed Web of Science ®Google Scholar
• PETERSON WL: The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol. Ther. (1997) 11 (Suppl. 1):21-25.
   PubMed Web of Science ®Google Scholar
• MIDOLO PD, TURNIDGE JD, LAMBERT JR: Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro. J. Antimicrob. Chemother. (1997) 39:331-337.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, BUCKER R, GROLL C et al.: Rapid loss of motility of Helicobacter pylori in the gastric lumen in vivo. Infect. Immun. (2005) 73:1584-1589.
   Google Scholar
• SCHREIBER S, KONRADT M, GROLL C et al.: The spatial orientation of Helicobacter pylori in the gastric mucus. Proc. Natl. Acad. Sci. USA (2004) 101:5024-5029.
   Google Scholar
• GODDARD AF, JESSA MJ, BARRETT DA, SHAW PN et al.: Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology (1996) 111(2):358-367.
   PubMed Web of Science ®Google Scholar
• GODDARD AF, SPILLER RC: The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol. Ther. (1996) 10:105-109.
   PubMed Web of Science ®Google Scholar
• GODDARD AF, SPILLER RC: In vitro assessment of gastric mucosal transfer of anti-Helicobacter therapeutic agents. Antimicrob. Agents Chemother. (1997) 41:1246-1249.
   PubMedGoogle Scholar
• SHERWOOD PV, WIBAWA JI, ATHERTON JC et al.: Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats. Gut (2002) 51:490-495.
   PubMed Web of Science ®Google Scholar
• ERAH PO, GODDARD AF, BARRETT DA, SHAW PN, SPILLER RC: The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. (1997) 39:5-12.
   PubMed Web of Science ®Google Scholar
• GUSTAVSON LE, KAISER JF, EDMONDS AL et al.: Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother. (1995) 39(9):2078-2083.
   PubMed Web of Science ®Google Scholar
• TREIBER G, GLADZIWA U, ITTEL TH et al.: Tripotassium dicitrato bismuthate: absorption and urinary excretion of bismuth in patients with normal and impaired renal function. Aliment Pharmacol. Ther. (1991) 5:491-502.
   PubMedGoogle Scholar
• TREIBER G, WALKER S, KLOTZ U: Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. Clin. Pharmacol. Ther. (1994) 55(5):486-491.
   PubMedGoogle Scholar
• PHILLIPS RH, WHITEHEAD MW, DOIG LA et al.: Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe? Helicobacter (2001) 6(2):151-156.
   PubMedGoogle Scholar
• TILLMAN LA, DRAKE FM, DIXON JS, WOOD JR: Review article: safety of bismuth in the treatment of gastrointestinal diseases. Aliment Pharmacol. Ther. (1996) 10(4):459-467.
   PubMedGoogle Scholar
• TREIBER G: The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am. J. Gastroenterol. (1996) 91(2):246-257.
   PubMed Web of Science ®Google Scholar
• AMMON S, TREIBER G, KEES F, KLOTZ U: Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. Aliment Pharmacol. Ther. (2000) 14:759-766.
   PubMed Web of Science ®Google Scholar
• DORE MP, KWON DH, SEPULVEDA AR, GRAHAM DY, REALDI G: Stable amoxicillin resistance in Helicobacter pylori. Helicobacter (2001) 6(1):79.
   PubMedGoogle Scholar
• NAKAMURA M, SPILLER RC, BARRETT DA et al.: Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter (2003) 8(4):294-299.
   PubMed Web of Science ®Google Scholar
• TREIBER G, AMMON S, KLOTZ U: Age-dependent eradication of Helicobacter pylori with dual therapy. Aliment Pharmacol. Ther. (1997) 11(4):711-718.
   PubMedGoogle Scholar
• COOREMAN MP, KRAUSGRILL P, HENGELS KJ: Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob. Agents Chemother. (1993) 37:1506-1509.
   PubMed Web of Science ®Google Scholar
• HULTEN K, RIGO R, GUSTAFSSON I, ENGSTRAND L: New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. Antimicrob. Agents Chemother. (1996) 40:2727-2731.
   PubMedGoogle Scholar
• MAINZ D, BORNER K, KOEPPE P, KOTWAS J, LODE H: Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. J. Antimicrob. Chemother. (2002) 50(5):699-706.
   PubMedGoogle Scholar
• ORTIZ RA, CALAFATTI SA, CORAZZI A et al.: Amoxicillin and ampicillin are not transferred to gastric juice irrespective of Helicobacter pylori status or acid blockade by omeprazole. Aliment Pharmacol. Ther. (2002) 16(6):1163-1170.
   PubMedGoogle Scholar
• POMMERIEN W, BRAUN M, IDSTROM JP, WRANGSTADH M, LONDONG W: Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects. Aliment Pharmacol. Ther. (1996) 10(3):295-301.
   PubMedGoogle Scholar
• LAINE L, FENNERTY MB, OSATO M et al.: Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am. J. Gastroenterol. (2000) 95(12):3393-3398.
   PubMed Web of Science ®Google Scholar
• TREIBER G, WITTIG J, AMMON S, WALKER S, VAN DOORN LJ, KLOTZ U: Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch. Intern. Med. (2002) 162(2):153-160.
   PubMed Web of Science ®Google Scholar
• MEGRAUD F: Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol. Ther. (1997) 11(Suppl. 1):43-53.
   PubMed Web of Science ®Google Scholar
• MEGRAUD F, ROBERTS P, WILLIAMSON R: Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter (2000) 5:222-226.
   PubMed Web of Science ®Google Scholar
• CALABRESI L, PAZZUCCONI F, FERRARA S, DI PAOLO A, TACCA MD, SIRTORI C: Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Pharmacol. Res. (2004) 49:493-499.
   PubMedGoogle Scholar
• MARKHAM A, MCTAVISH D: Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs (1996) 51:161-178.
   PubMed Web of Science ®Google Scholar
• MEGRAUD F: Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. Drug Resist Updat. (2001) 4:178-186.
   PubMed Web of Science ®Google Scholar
• KWON DH, HULTEN K, KATO M et al.: DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates. Antimicrob. Agents Chemother. (2001) 45:2609-2615.
   PubMed Web of Science ®Google Scholar
• MANES G, BALZANO A: Tinidazole: from protozoa to Helicobacter pylori-the past, present and future of a nitroimidazole with peculiarities. Expert Rev. Anti. Infect. Ther. (2004) 2:695-705.
   PubMedGoogle Scholar
• SPENARD J, AUMAIS C, MASSICOTTE J et al.: Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication. Br. J. Clin. Pharmacol. (2005) 60:374-377.
   PubMedGoogle Scholar
• VAN ZANTEN SJ, GOLDIE J, HOLLINGSWORTH J et al.: Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J. Clin. Pathol. (1992) 45:225-227.
   PubMedGoogle Scholar
• XIA HH, YU WONG BC, TALLEY NJ, LAM SK: Alternative and rescue treatment regimens for Helicobacter pylori eradication. Expert Opin. Pharmacother. (2002) 3:1301-1311.
   PubMedGoogle Scholar
• BROGDEN RN, FITTON A: Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1994) 47(6):983-1009.
   PubMed Web of Science ®Google Scholar
• VON ROSENSTEIL NA, ADAM D: Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf. (1995) 13(2):105-122.
   PubMedGoogle Scholar
• BOCK H, KOOP H, LEHN N, HEEP M: Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J. Clin. Gastroenterol. (2000) 31:222-225.
   PubMed Web of Science ®Google Scholar
• GISBERT JP, GISBERT JL, MARCOS S, OLIVARES D, PAJARES JM: Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol. Ther. (2005) 22:1041-1046.
   PubMed Web of Science ®Google Scholar
• GISBERT JP, GISBERT JL, MARCOS S, PAJARES JM: Empirical Helicobacter pylori ‘rescue’ therapy after failure of two eradication treatments. Dig. Liver Dis. (2004) 36:7-12.
   PubMedGoogle Scholar
• GISBERT JP, PAJARES JM: Review article: Helicobacter pylori ‘rescue’ regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol. Ther. (2002) 16:1047-1057.
   PubMed Web of Science ®Google Scholar
• GISBERT JP, PAJARES JM: Helicobacter pylori ‘rescue’ therapy after failure of two eradication treatments. Helicobacter (2005) 10:363-372.
   PubMed Web of Science ®Google Scholar
• MEGRAUD F: Update on Therapeutic Options for Helicobacter pylori-related Diseases. Curr. Infect. Dis. Rep. (2005) 7:115-120.
   PubMedGoogle Scholar
• PERRI F, FESTA V, CLEMENTE R et al.: Randomized study of two ‘rescue’ therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am. J. Gastroenterol. (2001) 96:58-62.
   PubMed Web of Science ®Google Scholar
• QASIM A, SEBASTIAN S, THORNTON O et al.: Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol. Ther. (2005) 21:91-96.
   PubMed Web of Science ®Google Scholar
• WONG WM, GU Q, LAM SK et al.: Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy versus quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol. Ther. (2003) 17:553-560.
   PubMed Web of Science ®Google Scholar
• CALAFATTI SA, ORTIZ RA, DEGUER M, MARTINEZ M, PEDRAZZOLI JJ: Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. Br. J. Clin. Pharmacol. (2001) 52(2):205-209.
   PubMedGoogle Scholar
• ISAKOV V, DOMAREVA I, KOUDRYAVTSEVA L, MAEV I, GANSKAYA Z: Furazolidone-based triple ‘rescue therapy’ versus quadruple ‘rescue therapy’ for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol. Ther. (2002) 16:1277-1282.
   PubMedGoogle Scholar
• MALEKZADEH R, ANSARI R, VAHEDI H et al.: Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol. Ther. (2000) 14:299-303.
   PubMed Web of Science ®Google Scholar
• MEGRAUD F: Basis for the management of drug-resistant Helicobacter pylori infection. Drugs (2004) 64(17):1893-1904.
   PubMed Web of Science ®Google Scholar
• TREIBER G, AMMON S, MALFERTHEINER P, KLOTZ U: Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter (2002) 7(4):225-231.
   PubMed Web of Science ®Google Scholar
• ALTAMIRANO A, BONDANI A: Adverse reactions to furazolidone and other drugs. A comparative review. Scand. J. Gastroenterol. Suppl. (1989) 169:70-80.
   PubMedGoogle Scholar
• GISBERT JP, MORENA F: Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol. Ther. (2006) 23:35-44.
   PubMed Web of Science ®Google Scholar
• CROOM KF, GOA KL: Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs (2003) 63(24):2769-2802.
   PubMed Web of Science ®Google Scholar
• OSATO MS, REDDY R, REDDY SG, PENLAND RL, MALATY HM, GRAHAM DY: Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch. Intern. Med. (2001) 161:1217-1220.
   PubMed Web of Science ®Google Scholar
• WU JY, KIM JJ, REDDY R, WANG WM, GRAHAM DY, KWON DH: Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob. Agents Chemother. (2005) 49:578-583.
   PubMedGoogle Scholar
• DE BOER WA, BORODY TJ: Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy. Dig. Liver Dis. (2000) 32(8):673-675.
   PubMedGoogle Scholar
• DORE MP, LEANDRO G, REALDI G, SEPULVEDA AR, GRAHAM DY: Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig. Dis. Sci. (2000) 45(1):68-76.
   PubMed Web of Science ®Google Scholar
• DUCK WM, SOBEL J, PRUCKLER JM et al.: Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg. Infect. Dis. (2004) 10(6):1088-1094.
   PubMed Web of Science ®Google Scholar
• FISCHBACH LA, VAN ZANTEN S, DICKASON J: Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol. Ther. (2004) 20(10):1071-1082.
   PubMed Web of Science ®Google Scholar
• GLOCKER E, KIST M: Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J. Clin. Microbiol. (2004) 42:2241-2246.
   PubMedGoogle Scholar
• GRAHAM DY: Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology (1998) 115:1272-1277.
   PubMed Web of Science ®Google Scholar
• HOFFMAN PS: Antibiotic resistance mechanisms of Helicobacter pylori. Can. J. Gastroenterol. (1999) 13:243-249.
   PubMedGoogle Scholar
• HOUBEN MH, VAN DE BEEK D, HENSEN EF, CRAEN AJ, RAUWS EA, TYTGAT GN: A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol. Ther. (1999) 13:1047-1055.
   PubMed Web of Science ®Google Scholar
• HUANG JQ, HUNT RH: Treatment after failure: the problem of ‘non-responders’. Gut (1999) 45 (Suppl. 1):I40-I44.
   Web of Science ®Google Scholar
• HUNT RH, SMAILL FM, FALLONE CA et al.: Implications of antibiotic resistance in the management of Helicobacter pylori infection: Canadian Helicobacter Study Group. Can. J. Gastroenterol. (2000) 14(10):862-868.
   PubMedGoogle Scholar
• MEGRAUD F: H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut (2004) 53(9):1374-1384.
   PubMed Web of Science ®Google Scholar
  ••Excellent review summarising the current knowledge of H.pylori resistance (basic and clinical research).
   Google Scholar
• WOLLE K, LEODOLTER A, MALFERTHEINER P, KONIG W: Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J. Med. Microbiol. (2002) 51:705-709.
   PubMed Web of Science ®Google Scholar
• CALVET X, GARCIA N, LOPEZ T et al.: A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol. Ther. (2000) 14(5):603-609.
   PubMed Web of Science ®Google Scholar
• GENE E, CALVET X, AZAGRA R, GISBERT JP: Triple versus quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol. Ther. (2003) 17(9):1137-1143.
   PubMed Web of Science ®Google Scholar
• GISBERT JP, GONZALEZ L, CALVET X: Systematic review and meta-analysis: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter (2005) 10:157-171.
   PubMed Web of Science ®Google Scholar
• GISBERT JP, PAJARES JM: Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol. Ther. (2005) 21:795-804.
   PubMedGoogle Scholar
• GISBERT JP, GONZALEZ L, CALVET X et al.: Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol. Ther. (2000) 14(10):1319-1328.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, HAMMOUD F, EL-ZIMAITY HM et al.: Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol. Ther. (2003) 17(10):1229-1236.
   PubMed Web of Science ®Google Scholar
• HUANG J, HUNT RH: The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol. Ther. (1999) 13(6):719-729.
   PubMed Web of Science ®Google Scholar
• JANSSEN MJ, LAHEIJ RJ, DE BOER WA, JANSEN JB: Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication. Aliment Pharmacol. Ther. (2005) 21:341-345.
   PubMed Web of Science ®Google Scholar
• LAHEIJ RJ, ROSSUM LG, JANSEN JB, STRAATMAN H, VERBEEK AL: Evaluation of treatment regimens to cure Helicobacter pylori infection- a meta-analysis. Aliment Pharmacol. Ther. (1999) 13:857-864.
   PubMed Web of Science ®Google Scholar
• MOAYYEDI P, SOO S, DEEKS J, DELANEY B et al.: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst. Rev. (2005)1:CD002096.
   PubMedGoogle Scholar
• PIPKIN GA, WILLIAMSON R, WOOD JR: Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol. Ther. (1998) 12:823-837.
   PubMedGoogle Scholar
• KATELARIS PH, FORBES GM, TALLEY NJ, CROTTY B: A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology (2002) 123(6):1763-1769.
   PubMed Web of Science ®Google Scholar
• DE BOER WA: Eradication therapy should be different for dyspeptic patients than for ulcer patients. Can. J. Gastroenterol. (2003) 17 (Suppl. B):41B-45B.
   Google Scholar
• HUANG JQ, ZHENG GF, HUNT RH et al.: Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J. Gastroenterol. (2005) 11:2726-2732.
   Google Scholar
• SUZUKI T, MATSUO K, SAWAKI A et al.: Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol. Ther. (2006) 24:273-80
   PubMed Web of Science ®Google Scholar
• TREIBER G, MALFERTHEINER P: CagA status and successful eradication of Helicobacter pylori. Aliment Pharmacol. Ther. (2006) 24:1261-1263
   PubMedGoogle Scholar
• GRAHAM DY: Therapy of Helicobacter pylori: current status and issues. Gastroenterology (2000) 118(2 Suppl. 1):S2-S8.
   Google Scholar
• TREIBER G: Treating H. pylori shorter than one week-a real future perspective? Z. Gastroenterol. (2000) 38(9):807-812.
   Google Scholar